Lentiviral Vector– tag –
-
Viral Vector Packaging Services Market Signals Rapid Growth Driven by Gene Therapy Commercialization and Increased Biomanufacturing Investment
openPR.com USA Overview This article provides an overview of a market research report from openPR.com. The global viral vector packaging services market is experiencing rapid growth, driven by advancing gene therapy commercialization and... -
Huazhong University of Science and Technology Tongji Hospital Demonstrates In Vivo CAR-T Therapy, Achieving Cost Reduction and Immune Reset for Multiple Sclerosis
Chosunbiz South Korea Overview A research team at Huazhong University of Science and Technology Tongji Hospital has demonstrated in vivo CAR-T therapy for autoimmune diseases like multiple sclerosis, successfully reducing manufacturing a... -
CDMO Signal Ranks Viral Vector CDMOs: Thermo Fisher Scientific, AGC Biologics, and Takeda Lead Top Tier
CDMO Signal USA Overview CDMO Signal released its latest ranking of viral vector CDMOs, including AAV, lentiviral, and adenoviral modalities. Thermo Fisher Scientific, AGC Biologics, and Takeda secured top positions in the overall Signal... -
Virica Biotech Announces CAR-T Lentivirus Manufacturing Innovations and AAV Production Optimization with FUJIFILM
Virica Biotech Canada Overview Virica Biotech has announced innovative advancements in lentiviral vector manufacturing for CAR-T therapies, highlighted by a May 19, 2026, poster presentation featuring high productivity and smarter purifi... -
PackGene Biotech’s π-alpha 293 Platform Achieves 10x AAV Production Amplification, Up to 1e+17vg/Batch, Supporting Remedium Bio’s Gene Therapy Advancement
PackGene Biotech China Overview PackGene Biotech announced its innovative π-alpha 293 AAV high-yield platform, capable of amplifying adeno-associated virus (AAV) production up to 10-fold and achieving an impressive yield of up to 1e+17vg... -
Oxford Biomedica Launches Fast-Track Viral Vector Service, Accelerating Gene Therapy Development by Cutting Manufacturing Times by up to 8 Months
Kalkine UK Overview Oxford Biomedica has launched a fast-track viral vector service to accelerate gene therapy development. This new service shortens GMP-grade manufacturing for AAV vectors from approximately 15 months to as little as 7 ... -
Gene Therapy’s Production Puzzle: Why AAV Outscales Lentiviral Vectors in Large-Scale Manufacturing
Industry Analysis USA Overview A recent analysis comparing AAV and lentiviral vector manufacturing platforms, both produced via transient transfection of HEK293 cells, reveals critical downstream manufacturing distinctions. AAV's stable ... -
Gene Therapy Manufacturing: Viral Vector CDMOs Confront Oversupply Amidst Rapid Expansion
IntuitionLabs USA Overview A recent industry report offers a comparative analysis of the AAV and lentiviral vector CDMO market, revealing trends of consolidation and emerging capacity oversupply. It highlights key players like FUJIFILM D... -
Vector BioMed’s LENTIVERSE™ Platform Accelerates CAR-T Manufacturing from Gene Sequence to Clinic-Ready in Under 12 Months
Vector BioMed USA Overview Vector BioMed has launched LENTIVERSE™, a lentiviral vector platform designed to dramatically accelerate CAR-T cell therapy manufacturing, aiming for completion from gene sequence to clinic-ready in less than 1... -
Drug Discovery News Identifies Critical Bottlenecks in Cell & Gene Therapy Manufacturing: Low Viral Vector Purification Yields and Plasmid DNA Supply Shortages
Drug Discovery News USA Overview Drug Discovery News highlights severe bottlenecks in cell and gene therapy (CGT) manufacturing, specifically in viral vector production. Low downstream purification yields for adeno-associated virus (AAV)...
